Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biopharmaceuticals
Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from the Children's Hospital Foundation for $182 Million
May 7th, 2008
The Children's Hospital Foundation, the parent company of The Children's Hospital of Philadelphia(R), and Royalty Pharma announced that the Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq(R) from and after October 1, 2007, to Royalty Pharma for $182 million in cash. "With the addition of this royalty on RotaTeq(R), we further our strategy of building a highly diversified portfolio of royalty interests on leading biopharmaceutical products. We are pleased to add the first vaccine to complement our royalties on products that treat a wide range of diseases, including cancer, rheumatoid arthritis and other autoimmune disorders, AIDS/HIV and...
Source: Vaccine Weekly (2008-05-07)
|
